Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FluoroPharma, the molecular imaging group of QuantRx Biomedical, has entered into a license agreement with Massachusetts General Hospital for the development and commercialization of agents for diagnosis and treatment of Alzheimer's disease.
Subscribe to our email newsletter
The licensed technologies, which were co-developed by FluoroPharma and Massachusetts General Hospital (MGH) scientists, target multiple biological processes associated with Alzheimer’s disease. According to the available sources, currently, there is no single diagnostic test that proves a person has Alzheimer’s.
Kundakovic, FluoroPharma’s president, said: “The technology has the potential to be highly effective due to the agents enhanced accumulation in the brain. In combination with high resolution PET imaging, these agents may provide valuable information in patients where early diagnostic and therapeutic information is likely to have the greatest benefit.”